Clinical trial
Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell…
NCT00082940 · Wake Forest University Health Sciences, Other · Completed
Key facts
| NCT number | NCT00082940 |
|---|---|
| Title | Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia |
| Official title | A Phase II Study of ONTAK® (Denileukin Diftitox, DABIL-2) in Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | Wake Forest University Health Sciences, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | denileukin diftitox |
| Start date | Aug 1, 2002 |
| Primary completion | Jan 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | May 19, 2004 |
| Last update posted | Jan 19, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: